What effect will Covid-19 have on force majeure?

24 July 2020
catherine_penny_elizabeth_butler_large

Catherine Penny (on left in picture above), partner, and Elizabeth Butler, associate, Stevens and Bolton LLP, provide an Expert View on an important issue thrown up by the pandemic.

Pharmaceutical, healthcare and biotech companies are, like many businesses across a breadth of industries, continuing to feel the effects of the Covid-19 pandemic.

The global crisis has prompted prolonged disruption to supply chains, causing parties to scrutinize each other’s rights and obligations under their existing contracts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical